Project Grant R01CA296797
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $681K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the University of California, San Francisco (UCSF) to genetically engineer myeloid cells, including macrophages and dendritic cells, for the treatment of solid tumors. The $0.00 award, with a project period from August 1, 2025 to July 31, 2028, aims to apply advanced genetic engineering tools to reprogram myeloid cells and enhance their tumoricidal activities and resistance to...
- This federal Project Grant award of $677,787 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of California, San Francisco (UCSF) to study the role of AIRE-expressing macrophages in tumor immune evasion. The research aims to define novel mechanisms by which tumors evade immune responses, with a focus on the function of these unique macrophage populations in the tumor microenvironment. The project will run from August 2025 through...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $151,040 to The Regents of the University of California, San Francisco (UCSF) to develop improved methods for profiling cell surface proteins and proteolysis. The goal is to better understand how cancer cell surface proteins and their cleavage are remodeled by proliferative oncogenes, which could shed light on disease progression and therapeutic resistance. The project will...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- The University of California, Irvine (UCI) was awarded a $2,186,372 Project Grant under the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396). The 5-year grant, which began on April 1, 2025, will support a research program focused on understanding the fundamental biological mechanisms of cancer initiation and progression. The program includes three interdisciplinary research projects that will leverage mouse models to investigate the role of stochastic,...
- The University of California, Los Angeles (UCLA) was awarded a $647,632 Project Grant by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) on March 11, 2025. The grant supports research to develop novel "TNF-ALPHA-ARMED" T-cell receptor (TCR) vectors to enhance the efficacy of adoptive cell therapy for solid tumors. Specifically, the research aims to evaluate the impact of transgenic TNF-alpha co-delivery with tumor antigen-specific TCRs or chimeric antigen...
- The National Institutes of Health (NIH) National Cancer Institute awarded a $618,928 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, Berkeley. The 5-year grant, awarded on June 9, 2025, will fund research to investigate the mechanisms by which regulatory T cells (Tregs) within tumors suppress antitumor immune responses. The project aims to determine if blocking Treg function solely within the tumor microenvironment is sufficient to control...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...